DPD status and fluoropyrimidines-based treatment: high activity matters too

di Chamorey, Emmanuel, Francois, Eric, Etienne, Marie-Christine, Ferrero, Jean-Marc, Peyrade, Frederic, Barranger, Emmanuel, Bozec, Alexandre, Largillier, Rémy, Cassuto, Ophelie, Viotti, Julien, Schiappa, Renaud, Milano, Gérard
Pubblicato in BMC Cancer (2020)

All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to Ponatinib

di Cassuto, Ophélie, Dufies, Maeva, Jacquel, Arnaud, Robert, Guillaume, Ginet, Clémence, Dubois, Alix, Hamouda, Amine, Puissant, Alexandre, Luciano, Fredéric, Karsenti, Jean-Michel, Legros, Laurence, Cassuto, Jill Patrice, Lenain, Pascal, Auberger, Patrick
Pubblicazione 2012

Nous devons respecter le schéma vaccinal anti-SARS-CoV-2 sans décalage chez les patients atteints de cancer sous traitement

di Barrière, Jérôme, Audigier-Valette, Clarisse, Borchiellini, Delphine, Hoch, Benjamin, Castelnau, Olivier, Francois, Eric, Gastaud, Lauris, Skaf, Richard, Berdah, Jean-François, Marie, Wislez, Lescaut, Willy, Peyrade, Frédéric, Cluzeau, Thomas, Cassuto, Ophélie, Carles, Michel
Pubblicato in Bull Cancer (2021)

CXCL7 is a predictive marker of sunitinib efficacy in clear cell renal cell carcinomas

di Dufies, Maeva, Giuliano, Sandy, Viotti, Julien, Borchiellini, Delphine, Cooley, Linsay S, Ambrosetti, Damien, Guyot, Mélanie, Ndiaye, Papa Diogop, Parola, Julien, Claren, Audrey, Schiappa, Renaud, Gal, Jocelyn, Frangeul, Antoine, Jacquel, Arnaud, Cassuto, Ophélie, Grépin, Renaud, Auberger, Patrick, Bikfalvi, Andréas, Milano, Gérard, Escudier, Bernard, Rioux-Leclercq, Nathalie, Porta, Camillo, Negrier, Sylvie, Chamorey, Emmanuel, Ferrero, Jean-Marc, Pagès, Gilles
Pubblicato in Br J Cancer (2017)